According to Fintel data, Guggenheim initiated coverage of LB Pharmaceuticals (NASDAQGM:LBRX) on October 6, 2026, with a Buy recommendation.
The initiation follows a series of recent analyst moves surrounding the company. On October 5, 2026, Roth Capital downgraded the stock from Buy to Neutral. Prior to that, on October 2, 2026, Needham initiated coverage with a Buy rating. As of the most recent recorded close on October 5, 2026, the stock traded at $34.62. Over a one-week period from the September 28, 2026 baseline close of $37.89, shares declined 8.63%. Over a one-month period from the September 4, 2026 baseline close of $49.34, the price fell 29.83%.
As of October 2, 2026, the consensus mean target for the stock stands at $56.21, with a median of $55.08, implying a potential upside of 62.37%. Broader recommendation data as of September 1, 2026, reflects 15 total ratings comprising 5 strong buys, 9 buys, and 1 hold. This aggregates to 93.3% positive recommendations and 6.7% hold ratings.
LB Pharmaceuticals last filed earnings on August 11, 2026, reporting an actual EPS of -1.71 versus an estimate of -0.8194. The next earnings announcement is scheduled for November 4, 2026.
Recent analyst actions
Recent analyst upgrades, downgrades, initiations, and maintained ratings
| Date | Analyst | Prior Recommendation | Latest Recommendation | Action |
|---|---|---|---|---|
| October 6, 2026 | Guggenheim | – | Buy | Initiated coverage |
| October 5, 2026 | Roth Capital | Buy | Neutral | Downgrade |
| October 2, 2026 | Needham | – | Buy | Initiated coverage |